TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23131885
Drug: N-acetylcysteine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (up to 2400 mg/d)
Study: 12949359
Drug: High sterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High sterol margarine (1.5 g/d plant sterols + 0.5 g/d plant stanols)
Study: 12949359
Drug: Low sterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sterol margarine (1 g/d plant sterols + 1 g/d plant stanols)
Study: 30819227
Drug: Venturi mask
Normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venturi mask oxygen therapy
Study: 15944779
Drug: 5-FU continuous
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU continuous infusion (320 mg/m2/day) for 14 days followed by oral HCFU (300 mg/day) for one year
Study: 15944779
Drug: 5-FU continuous
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU continuous infusion alone for 14 days
Study: 10646729
Drug: Specific local
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific local nasal immunotherapy (LNIT) for 8 months
Study: 10646729
Drug: Specific local
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific local nasal immunotherapy (LNIT) for allergy to mites
Study: 10646729
Drug: Specific local
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific local nasal immunotherapy (LNIT)
Study: 3729199
Drug: Caffeine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (250 mg, 30 minutes before breakfast)
Study: 25683315
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (NS) injection
Study: 16469442
Drug: Citalopram (CIT)
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citalopram (CIT) 40 mg
Study: 16469442
Drug: Melatonin (MT)
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin (MT) 1 mg
Study: 12680886
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (FP) 1000 microg day‐1 for 7 days
Study: 12680886
Drug: Intravenous fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fluticasone propionate 1000 microg
Study: 10846595
Drug: Genotype-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype-guided treatment
Study: 9106575
Drug: Pari LC
Normalized name: Pari LC Pediatric Set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pari LC nebulizer system (300 mg tobramycin in 5 mL of 1/4 normal saline)
Study: 9106575
Drug: Sidestream nebulizer
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sidestream nebulizer system (300 mg tobramycin in 5 mL of 1/4 normal saline)
Study: 9106575
Drug: UltraNeb 99/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: UltraNeb 99/100 nebulizer system (600 mg tobramycin in 30 mL of 1/2 normal saline)
Study: 8229026
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of prednisone and azathioprine
Study: 31104856
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of levo-pantoprazole
Study: 31104856
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of racemic pantoprazole
Study: 22339386
Drug: Control (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (saline solution storage)
Study: 9469347
Drug: Pamidronate 90
Normalized name: pamidronate 90 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate 90 mg intravenously administered as a 4-hour infusion monthly for 21 cycles
Study: 8585642
Drug: Mupirocin ointment
Normalized name: Mupirocin Ointment
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin ointment alone
Study: 8585642
Drug: Mupirocin ointment
Normalized name: Mupirocin Ointment
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mupirocin ointment plus chlorhexidine baths
Study: 2096108
Drug: Heptaminol (626
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heptaminol (626 mg dose)
Study: 582541
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg of pimozide
Study: 582541
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg of pimozide
Study: 582541
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (3 mg and 8 mg)
Study: 26711509
Drug: PfSPZ chemoprophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfSPZ chemoprophylaxis vaccine (CVac) - 3× monthly immunizations with 7.5 × 10(4) PfSPZ
Study: 26711509
Drug: PfSPZ chemoprophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: PfSPZ chemoprophylaxis vaccine (CVac)
Study: 19196113
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) - 12 J (4 J/cm²) applied intraorally and extraorally immediately after surgery
Study: 15207420
Drug: Moderate intensity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate intensity exercise program (combination of aerobic/endurance activities, strength training, balance, and flexibility training)
Study: 2687898
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil 20 mg/kg/day
Study: 2687898
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil 40 mg/kg/day
Study: 2687898
Drug: Cefaclor 30
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor 30 mg/kg/day
Study: 2687898
Drug: Cefetamet pivoxil
Normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefetamet pivoxil (both doses)
Study: 27797396
Drug: Doxycycline 40
Normalized name: Doxycycline 40 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 40 mg
Study: 16385102
Drug: Combination analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination analgesic therapy; specific drugs and dosages not available.
Study: 16385102
Drug: Individual component
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual component drugs; specific drugs and dosages not available.
Study: 12626202
Drug: Corline Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corline Heparin Surface (CHS) with standard level of heparin
Study: 12626202
Drug: Corline Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corline Heparin Surface (CHS) with high level of heparin
Study: 12626202
Drug: Corline Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corline Heparin Surface (CHS) with low level of heparin
Study: 10520620
Drug: Pear juice
Normalized name: PEAR JUICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pear juice (120 mL)
Study: 10520620
Drug: White grape
Normalized name: Herbal Essences White Grapefruit Shampoo
DrugBank: Wine grape (DB10634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: White grape juice (120 mL)
Study: 7863649
Drug: Nurse-administered bed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-administered bed bath
Study: 7863649
Drug: Nurse-administered interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-administered interventions (overall)
Study: 7075123
Drug: Methadone (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (35 to 80 mg)
Study: 7075123
Drug: Methadone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (10 and 20 mg/day)
Study: 31771598
Drug: Supplement containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement containing caffeine, theanine and tyrosine (SUP)
Study: 26228414
Drug: High-dose antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose antidepressant therapy
Study: 26228414
Drug: Low-dose antidepressant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose antidepressant therapy
Study: 26228414
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses (high, low, placebo)
Study: 9489594
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg tamsulosin (as Omnic modified release capsules)
Study: 9489594
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg terazosin (as Flotrin tablets)
Study: 3254832
Drug: AWD 26‐06
Approvals — FDA: no, EMA: no, PMDA: no
Description: AWD 26‐06 (50 mg and above)
Study: 3254832
Drug: AWD 26‐06
Approvals — FDA: no, EMA: no, PMDA: no
Description: AWD 26‐06 (100 mg and 150 mg)
Study: 3254832
Drug: AWD 26‐06
Approvals — FDA: no, EMA: no, PMDA: no
Description: AWD 26‐06 (150 mg)
Study: 3254832
Drug: AWD 26‐06
Approvals — FDA: no, EMA: no, PMDA: no
Description: AWD 26‐06 (25 mg)
Study: 26691357
Drug: Intralesional triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intralesional triamcinolone acetonide (10 mg/ml)
Study: 26691357
Drug: Topical betamethasone
Normalized name: betamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical betamethasone valearate cream 0.1% twice daily
Study: 23434331
Drug: Unpreserved timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Unpreserved timolol 0.1% gel
Study: 15259840
Drug: Fluoxetine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine plus cognitive-behavioural therapy (CBT+meds)
Study: 15259840
Drug: Fluoxetine (meds
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (meds only)
Study: 15259840
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (CBT+meds and meds only)
Study: 14655830
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g L-tryptophan
Study: 14655830
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g L-tryptophan
Study: 14655830
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g L-tryptophan
Study: 7951084
Drug: Salbutamol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (400 micrograms per day) + Beclocort (1 mg per day)
Study: 7951084
Drug: Salbutamol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (400 micrograms per day) + Nedocromil (Tilade 8 mg per day)
Study: 7951084
Drug: Salbutamol alone
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol alone or in combination with an anti-inflammatory agent
Study: 2660997
Drug: Zinc chloride
Normalized name: Zinc Chloride
DrugBank: Zinc chloride (DB14533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc chloride spray and magnesium hydroxide ointment applied twice daily for seven consecutive days
Study: 28277603
Drug: Denosumab 60
Normalized name: denosumab 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 60 mg subcutaneously every 6 months during the FREEDOM trial
Study: 21493792
Drug: Intensive lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive lipid therapy
Study: 25007392
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg
Study: 15274684
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of enalapril 10 mg and losartan 100 mg daily
Study: 11016325
Drug: Eptifibatide (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eptifibatide (180 microg/kg bolus plus 2 microg/kg/min infusion)
Study: 8872656
Drug: Carbohydrate (CHO)
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (CHO) - 75 g glucose solution ingested 30 min before exercise
Study: 8872656
Drug: Control (Con)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (Con) - sweet placebo solution ingested 30 min before exercise
Study: 1618465
Drug: Sodium benzoate
Normalized name: Sodium Benzoate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium benzoate (5 gm twice daily)
Study: 1618465
Drug: Lactulose (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (dose adjusted for 2 or 3 semiformed stools/day)
Study: 6662184
Drug: hydrochlorothiazide-amiloride combination
Normalized name: amiloride / hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydrochlorothiazide-amiloride combination
Study: 31965649
Drug: Multiple-dose cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple-dose cefazolin (3 days)
Study: 28157791
Drug: Liposome bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposome bupivacaine (10 mL of liposome bupivacaine 133 mg) added to 5 mL of 0.25% bupivacaine HCl
Study: 28157791
Drug: Standard bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard bupivacaine (15 mL of 0.25% bupivacaine HCl) alone
Study: 24332192
Drug: Group exercise
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group exercise program (G)
Study: 21823282
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at Tianshu (ST 25) and Dachangshu (BL 25), once daily for 4 weeks.
Study: 21823282
Drug: Trimebutine Maleate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimebutine Maleate, 2 capsules, 3 times per day for 4 weeks.
Study: 14709946
Drug: Sertraline (Zoloft)
Normalized name: sertraline Oral Solution [Zoloft]
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline (Zoloft) 50 to 200 mg/d
Study: 2724108
Drug: Xylocaine (lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylocaine (lidocaine hydrochloride) administered as a posterior tibial block
Study: 2724108
Drug: Sensorcaine (bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensorcaine (bupivacaine hydrochloride) administered as a posterior tibial block
Study: 26338094
Drug: Patisiran 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patisiran 0.3 mg/kg every 3 weeks (Q3W)
Study: 31843791
Drug: PPV alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPV alone (conventional treatment)
Study: 16454979
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus clopidogrel (loading dose of 300 mg aspirin and 300 mg clopidogrel, then 100 mg aspirin and 75 mg clopidogrel per day)
Study: 16454979
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (loading dose of 300 mg aspirin, then 100 mg per day)
Study: 16454979
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (30 healthy volunteers on no medications)
Study: 8957697
Drug: Oral Vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Vitamin E treatment
Study: 1533427
Drug: ANP value
Normalized name: diphenhydramine hydrochloride Oral Capsule [Valu-Dryl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANP value greater than 200 pmol/L
Study: 2410520
Drug: Thiazina (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazina (combination tablet of thiacetazone and INH) daily for 12 months
Study: 2410520
Drug: Thiazina daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazina daily for 12 months plus rifampin daily during months 1 and 7
Study: 2410520
Drug: Rifampin daily
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin daily during months 1 and 7 but no Thiazina
Study: 2410520
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (dapsone monotherapy)
Study: 12975409
Drug: Alpha blocker
Normalized name: ALPHA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha blocker
Study: 29094283
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for depression and anxiety
Study: 27768695
Drug: CCX168 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCX168 (30 mg orally, twice daily)
Study: 27768695
Drug: CCX168 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCX168 (1 to 100 mg)
Study: 24456286
Drug: Teriparatide (TPT;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (TPT; 20 μg s.c.) for 6 months
Study: 23321196
Drug: Tolvaptan 3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan 3.75 mg/day
Study: 23551935
Drug: Tolvaptan 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolvaptan 7.5 mg/day
Study: 20837928
Drug: Atorvastatin 0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 0, 5, or 50 μmol/L ex vivo
Study: 10440462
Drug: Gabapentin (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (900 to 3,600 mg daily in three divided doses)
Study: 2276107
Drug: Oral care
Normalized name: Oral Care Q4 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral care protocol A
Study: 2276107
Drug: Oral care
Normalized name: Oral Care Q4 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral care protocol B
Study: 2276107
Drug: Reinforcement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinforcement of oral care instructions and nursing assessments
Study: 22883421
Drug: Fentanyl 1
Normalized name: fentanyl 1.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1 mcg/kg
Study: 22883421
Drug: Fentanyl 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 0.5 mcg/kg
Study: 9931196
Drug: Acetaminophen (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (4 g/day)
Study: 18534086
Drug: BIS 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS 0.5 mg twice daily (b.i.d.)
Study: 18534086
Drug: BIS 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS 0.25 mg b.i.d. and 0.5 mg b.i.d.
Study: 18534086
Drug: BIS 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS 0.25 mg once daily (q.d.)
Study: 18534086
Drug: BIS 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS 0.5 mg q.d.
Study: 18534086
Drug: BIS 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIS 1.0 mg q.d.
Study: 17242413
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion (CEI) of 0.2% ropivacaine hydrochloride (10 mL/h without bolus)
Study: 17242413
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (10 mL of 0.2% ropivacaine hydrochloride per hour with 10-mL bolus)
Study: 3190996
Drug: Soluble aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble aspirin 900 mg
Study: 9545995
Drug: Risperidone (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (6 mg/day, adjusted to 6.4 mg/day)
Study: 9545995
Drug: Clozapine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (300 mg/day, adjusted to 291.2 mg/day)
Study: 11429337
Drug: Fenoldopam infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoldopam infusion
Study: 2574081
Drug: Control infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control infusion (0.9% saline)
Study: 7411761
Drug: Erythromycin stearate
Normalized name: Erythromycin Stearate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin stearate or estolate, 500 mg orally every six hours for five days (13 patients)
Study: 7411761
Drug: Crystalline aqueous
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalline aqueous penicillin G potassium, 1 million units intravenously every three hours for three days (10 patients)
Study: 31567921
Drug: Same-day dose
Normalized name: SAMe
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same-day dose of 4 L polyethylene glycol
Study: 31567921
Drug: Split-dose of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose of 4 L polyethylene glycol (2 L at 9:00 PM the day before and 2 L at 7:00 AM or 10:00 AM)
Study: 31567921
Drug: Split-dose of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose of 4 L polyethylene glycol
Study: 12185558
Drug: Oral artemisinin
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral artemisinin 500 mg daily for 3 days followed by oral mefloquine 750 mg on day 4
Study: 12185558
Drug: Oral artemisinin
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral artemisinin 500 mg daily for 3 days plus oral mefloquine 750 mg on day 1
Study: 12185558
Drug: Single 750-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 750-mg oral dose of mefloquine
Study: 12185558
Drug: Artemisinin and
Normalized name: artemisinin and piperaquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin and mefloquine combination
Study: 9455524
Drug: Azithromycin, 250
Normalized name: Azithromycin, 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin, 250 mg daily
Study: 9455524
Drug: Azithromycin, 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin, 1,000 mg weekly
Study: 9455524
Drug: Doxycycline, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline, 100 mg daily
Study: 1695877
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of terfenadine and flurbiprofen
Study: 1695877
Drug: All active
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All active drug days (terfenadine, flurbiprofen, combination)
Study: 320477
Drug: Antibiotics plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics plus daily granulocyte transfusions from ABO-matched donors